Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_assertion evidence source_evidence_literature NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_assertion SIO_000772 21245420 NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_assertion wasDerivedFrom befree-2016 NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_assertion wasGeneratedBy ECO_0000203 NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- befree-2016 importedOn "2016-02-19" NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.